Cell Reprogramming in New Therapies Development

The generation of iPSCs from differentiated mature cells is one of the most promising technologies for developing new therapies to treat a wide range of diseases. The rapid development of this technology allows the generation of patient-specific iPSCs that can be modified and differentiated into target cells by CRISPR/ Cas9 gene-editing tools to treat multiple degenerative and genetic diseases after transplantation, thus offsetting the risk of graft versus host disease. iPSCs in cell replacement therapy offer great potential for the correction of various diseases.

Direct reprogramming technology is also important biotechnology that has received much attention in recent years, and its widespread application provides a new direction for building models, treating diseases, and developing regenerative medicine. This technology provides a new choice for chronic diseases, such as diabetes, myocardial infarction and Parkinson's syndrome, which are very difficult to treat clinically. In general, somatic cells can be directly reprogrammed into specific functional somatic cells through cell direct reprogramming technology, which can replace necrotic and missing functional cells, so as to achieve the purpose of treating diseases.

Fig 1. Progress in iPSC-based therapies.Fig.1 Progress in iPSC-based therapies. (Rowe, 2019)

Development of New Therapies based on Cell Reprogramming

Cell Reprogramming in New Therapies Development

Given the great potential of cell reprogramming in the development of cell and gene replacement therapies for many degenerative and genetic diseases, researchers at Creative Bioarray are committed to developing new therapies for a wide range of diseases based on this technology. We isolate and culture somatic cells from patients with diseases, reprogram the cells into iPSCs by viral or non-viral mediated gene transfer, and then enrich the genetically modified iPSCs and differentiate them into affected cell subtypes. Alternatively, we can transdifferentiate a somatic cell directly into a functionally specific somatic cell by direct reprogramming. The resulting cells will be reinfused into the patient for the purpose of treating the disease. We focus on providing solutions for the development of new therapies for the following diseases:


  • A creative and experienced professional R&D team
  • Efficient solutions and delivery of detailed experimental data
  • Customer-focused service and cost-effectiveness

Based on a specialized and advanced cell reprogramming technology platform, Creative Bioarray is committed to helping our customers develop new therapies for a wide range of diseases. Our goal is to provide our customers with efficient and rational solutions in the field of cell reprogramming. If you need our scientific help, please contact us.


  1. Rowe, R.G.; Daley, G.Q. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019, 20(7): 377-388.
For Research Use Only. Not For Clinical Use.